ZFAND5
AN1-type zinc finger protein 5
Protein Summary
Involved in protein degradation via the ubiquitin-proteasome system. May act by anchoring ubiquitinated proteins to the proteasome. Plays a role in ubiquitin-mediated protein degradation during muscle atrophy. Plays a role in the regulation of NF-kappa-B activation and apoptosis. Inhibits NF-kappa-B activation triggered by overexpression of RIPK1 and TRAF6 but not of RELA. Inhibits also tumor necrosis factor (TNF), IL-1 and TLR4-induced NF-kappa-B activation in a dose-dependent manner. Overexpression sensitizes cells to TNF-induced apoptosis. Is a potent inhibitory factor for osteoclast differentiation.
- ENST00000237937
- ENSP00000237937
- ENSG00000107372
- ENST00000343431
- ENSP00000350586
- ENST00000376960
- ENSP00000366159
- ENST00000376962
- ENSP00000366161
- ZA20D2
- ZNF216
- ZA20D2
- ZNF216
- ZFAND5A
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor perturbation | 1 | ||
disease perturbation | 0.99 | ||
transcription factor binding site profile | 0.92 | ||
kinase perturbation | 0.88 | ||
microRNA | 0.78 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 12.93 (req: < 5)
Gene RIFs: 6 (req: <= 3)
Antibodies: 204 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 12.93 (req: >= 5)
Gene RIFs: 6 (req: > 3)
Antibodies: 204 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 10
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0